Boilerplate clauses

Boilerplate clauses

This subtopic focuses on boilerplate clauses in commercial business-to-business agreements. For information on commercial clauses more generally, see: Commercial clauses—overview.

For information on boilerplate in business-to-consumer contracts, see the section on ‘Consumer boilerplate’ below.

For information on boilerplate in public sector contracts, see the section on ‘Public sector boilerplate’ below.

The role of boilerplate

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements. All of those agreements should contain some boilerplate clauses.

‘Boilerplate’ is the term used to describe the clauses that are included in an agreement to deal with the mechanics of how it works and those legal points that are relevant to most transactions. For further consideration of the role and importance of boilerplate clauses, see Practice Note: The role of boilerplate.

Boilerplate clauses are generally found at the beginning and the end of an agreement. Such clauses are often thought of as standard, miscellaneous provisions, but this is a very dangerous view to adopt. It is not unusual for a boilerplate clause to be the cause of litigation. Since a boilerplate clause

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

Medical devices to get softer AI compliance regime, European Commission proposes

MLex: Manufacturers of medical devices would see compliance with the EU AI Act's high-risk regime eased under a European Commission proposal. Part of a broader update to medical-device laws, it reflects longstanding industry concerns and would lower regulatory burdens for the medical technology sector if confirmed by the European Parliament and Council of the EU.

ASA issues final guidance on less healthy food and drink advertising restrictions

TMT analysis: From the 5 January 2026, ads for ‘identifiable’ less healthy food and drink products will be banned from appearing on television between 5.30 am and 9.00 pm, on on-demand programme services between 5.30 am and 9.00 pm, and in paid online media at any time. Alongside exemptions for SME’s and media outside scope (such as radio, press and posters), the regime creates a safe harbour for ‘brand advertisements’. Brinsley Dresden, Rebecca Moore, and Helen Hart of Lewis Silkin consider the issues.

Landmark UK-US pharmaceutical deal

Life Sciences analysis: On 1 December 2025, the UK government announced a ‘landmark’ UK-US pharmaceutical deal. Under the deal, the UK claims to be (so far) the only country to secure zero-percent tariffs on pharmaceuticals exported to the US for the next three years. In return, the UK has committed to increase its spending on medicines and revise some of the most controversial aspects of the UK pricing and reimbursement system. Although details as to the implementation of the deal are still unclear, it is clear this will involve major changes to the landscape for commercializing innovator drugs in the UK, after months of attritional and sometimes fractious wrangling between the industry and UK government. Written by Grant Castle, Raj Gathani and Dan Spivey of Covington & Burling LLP.

Life Sciences weekly highlights—18 December 2025

This week's edition of Life Sciences weekly highlights includes news that the Council of the EU and the European Parliament have reached a provisional agreement on the proposed pharmaceutical legislation reform package, the European Commission has published proposed amendments to the medical device regulations, and it also has published the long-awaited draft Biotech Act along with a draft directive for genetically modified micro-organisms, together with announcing €10bn investment into the sector, which aim to boost EU biotech competitiveness, accelerate EU clinical trials and strengthen biosecurity. Further news included is that the European Parliament adopted an amended draft Critical Medicines Act, the MHRA has established a Regulatory Innovation Corridor with Singapore that allows companies to engage with both nation’s regulators simultaneously to obtain early joint advice and streamline clinical trial design for breakthrough health technologies, the Commission has published a draft implementing regulation establishing the operational framework for the European Health Data Space (EHDS) Board, the Commission has released the three-year working plan agendas for five working groups (Biosimilars, Biologics, joint CHMP/CVMP Quality, Non-clinical domain and Synthetic Peptides) and the ASA continues to sanction companies for advertisements of weight-loss medicines that are prescription-only medicines (POMs) and for claims that go beyond the medicine’s authorised indication, among other stories.